<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p139" style="overflow: hidden; position: relative; background-color: white; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_139{left:119px;bottom:1134px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2_139{left:799px;bottom:1132px;letter-spacing:-0.08px;}
#t3_139{left:162px;bottom:1085px;letter-spacing:0.13px;word-spacing:-0.01px;}
#t4_139{left:323px;bottom:1085px;letter-spacing:0.11px;word-spacing:-0.02px;}
#t5_139{left:162px;bottom:1067px;letter-spacing:0.11px;}
#t6_139{left:162px;bottom:1050px;letter-spacing:0.11px;word-spacing:1.04px;}
#t7_139{left:162px;bottom:1032px;letter-spacing:0.1px;word-spacing:0.03px;}
#t8_139{left:162px;bottom:1015px;letter-spacing:0.1px;}
#t9_139{left:221px;bottom:1015px;letter-spacing:0.12px;word-spacing:2.33px;}
#ta_139{left:162px;bottom:997px;letter-spacing:0.11px;word-spacing:0.09px;}
#tb_139{left:162px;bottom:979px;letter-spacing:0.12px;word-spacing:2.53px;}
#tc_139{left:162px;bottom:962px;letter-spacing:0.11px;word-spacing:0.25px;}
#td_139{left:162px;bottom:944px;letter-spacing:0.11px;word-spacing:2.7px;}
#te_139{left:162px;bottom:927px;letter-spacing:0.11px;word-spacing:0.02px;}
#tf_139{left:162px;bottom:909px;letter-spacing:0.11px;word-spacing:-0.26px;}
#tg_139{left:340px;bottom:909px;letter-spacing:0.1px;word-spacing:-0.27px;}
#th_139{left:162px;bottom:892px;letter-spacing:0.12px;word-spacing:5.11px;}
#ti_139{left:162px;bottom:874px;letter-spacing:0.12px;word-spacing:5.74px;}
#tj_139{left:162px;bottom:857px;letter-spacing:0.11px;word-spacing:0.53px;}
#tk_139{left:162px;bottom:839px;letter-spacing:0.1px;word-spacing:-0.54px;}
#tl_139{left:162px;bottom:821px;letter-spacing:0.11px;word-spacing:0.03px;}
#tm_139{left:162px;bottom:804px;letter-spacing:0.13px;}
#tn_139{left:295px;bottom:804px;letter-spacing:0.13px;word-spacing:4.1px;}
#to_139{left:162px;bottom:786px;letter-spacing:0.11px;word-spacing:0.03px;}
#tp_139{left:141px;bottom:729px;letter-spacing:0.15px;}
#tq_139{left:162px;bottom:709px;letter-spacing:0.14px;}
#tr_139{left:162px;bottom:674px;letter-spacing:0.13px;word-spacing:0.03px;}
#ts_139{left:334px;bottom:674px;letter-spacing:0.11px;word-spacing:0.03px;}
#tt_139{left:162px;bottom:656px;letter-spacing:0.11px;word-spacing:0.03px;}
#tu_139{left:162px;bottom:621px;letter-spacing:0.12px;}
#tv_139{left:251px;bottom:621px;letter-spacing:0.11px;word-spacing:-0.58px;}
#tw_139{left:162px;bottom:604px;letter-spacing:0.11px;word-spacing:1.1px;}
#tx_139{left:162px;bottom:586px;letter-spacing:0.11px;word-spacing:0.47px;}
#ty_139{left:162px;bottom:568px;letter-spacing:0.12px;word-spacing:2.82px;}
#tz_139{left:162px;bottom:551px;letter-spacing:0.1px;word-spacing:0.03px;}
#t10_139{left:162px;bottom:533px;letter-spacing:0.12px;}
#t11_139{left:242px;bottom:533px;letter-spacing:0.11px;word-spacing:0.73px;}
#t12_139{left:162px;bottom:516px;letter-spacing:0.11px;word-spacing:1.55px;}
#t13_139{left:162px;bottom:498px;letter-spacing:0.11px;word-spacing:-0.59px;}
#t14_139{left:162px;bottom:480px;letter-spacing:0.11px;word-spacing:1.99px;}
#t15_139{left:162px;bottom:463px;letter-spacing:0.08px;}
#t16_139{left:162px;bottom:446px;letter-spacing:0.12px;}
#t17_139{left:221px;bottom:446px;letter-spacing:0.12px;word-spacing:2.49px;}
#t18_139{left:162px;bottom:428px;letter-spacing:0.12px;word-spacing:1.74px;}
#t19_139{left:162px;bottom:410px;letter-spacing:0.11px;word-spacing:2.16px;}
#t1a_139{left:162px;bottom:393px;letter-spacing:0.1px;word-spacing:0.02px;}
#t1b_139{left:162px;bottom:375px;letter-spacing:0.12px;}
#t1c_139{left:240px;bottom:375px;letter-spacing:0.11px;word-spacing:-0.05px;}
#t1d_139{left:162px;bottom:358px;letter-spacing:0.11px;word-spacing:0.15px;}
#t1e_139{left:162px;bottom:340px;letter-spacing:0.11px;word-spacing:2.07px;}
#t1f_139{left:162px;bottom:322px;letter-spacing:0.1px;word-spacing:-0.35px;}
#t1g_139{left:162px;bottom:305px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1h_139{left:162px;bottom:287px;letter-spacing:0.14px;}
#t1i_139{left:291px;bottom:287px;letter-spacing:0.12px;word-spacing:0.04px;}
#t1j_139{left:141px;bottom:230px;letter-spacing:0.15px;}
#t1k_139{left:162px;bottom:210px;letter-spacing:0.13px;}
#t1l_139{left:162px;bottom:175px;letter-spacing:0.12px;word-spacing:0.03px;}
#t1m_139{left:162px;bottom:157px;letter-spacing:0.11px;word-spacing:0.03px;}
#t1n_139{left:162px;bottom:122px;letter-spacing:0.11px;word-spacing:0.11px;}
#t1o_139{left:162px;bottom:105px;letter-spacing:0.1px;word-spacing:0.65px;}
#t1p_139{left:162px;bottom:87px;letter-spacing:0.11px;word-spacing:2.56px;}

.s0_139{font-size:15px;font-family:TimesNewRomanPSMT_6e;color:#000;}
.s1_139{font-size:17px;font-family:Calibri_7k;color:#000;}
.s2_139{font-size:15px;font-family:TimesNewRomanPS-BoldMT_7s;color:#000;}
.s3_139{font-size:18px;font-family:TimesNewRomanPS-BoldMT_7w;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts139" type="text/css" >

@font-face {
	font-family: Calibri_7k;
	src: url("fonts/Calibri_7k.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7s;
	src: url("fonts/TimesNewRomanPS-BoldMT_7s.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7w;
	src: url("fonts/TimesNewRomanPS-BoldMT_7w.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPSMT_6e;
	src: url("fonts/TimesNewRomanPSMT_6e.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg139Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg139" style="-webkit-user-select: none;"><object width="935" height="1210" data="139/139.svg" type="image/svg+xml" id="pdf139" style="width:935px; height:1210px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_139" class="t s0_139">Brain: Chemistry to Cognition </span><span id="t2_139" class="t s1_139">131 </span>
<span id="t3_139" class="t s2_139">Materials and Methods: </span><span id="t4_139" class="t s0_139">Myeloperoxidase activity in human microglia was evaluated by microscopy using </span>
<span id="t5_139" class="t s0_139">our in-house probe. Bacterial toxin BMAA was used for our experiment to observe the production of HOCl, </span>
<span id="t6_139" class="t s0_139">loss of mitochondrial potential, and accelerated lipid-peroxidation in microglia by flow cytometer. Erastin </span>
<span id="t7_139" class="t s0_139">was taken as a positive control. </span>
<span id="t8_139" class="t s2_139">Results: </span><span id="t9_139" class="t s0_139">Treatment of bacterial-toxin BMAA increased in percentage (56%) of reactive oxygen species </span>
<span id="ta_139" class="t s0_139">(ROS) positive microglia. Further, 50% of microglia showed reduced mitochondrial potential 24 hours after </span>
<span id="tb_139" class="t s0_139">treatment with BMAA. We also found that BMAA induces myeloperoxidase activity and increases the </span>
<span id="tc_139" class="t s0_139">production of mitochondrial HOCl similar to erastin-treated microglia. Additionally, BMAA increases lipid </span>
<span id="td_139" class="t s0_139">peroxidation in microglia which is comparable to erastin treatment. Potential small molecule flavonoid </span>
<span id="te_139" class="t s0_139">decreases the BMAA-induced HOCl production and lipid peroxidation in microglia. </span>
<span id="tf_139" class="t s2_139">Discussion and conclusion: </span><span id="tg_139" class="t s0_139">BMAA is reported to enter the brain via crossing the blood-brain barrier (BBB) </span>
<span id="th_139" class="t s0_139">or gut-brain axis. BMAA increases ROS production and negatively regulates mitochondrial health. </span>
<span id="ti_139" class="t s0_139">Additionally, BMAA activates myeloperoxidase activity and lipid peroxidation in microglia. Lipid </span>
<span id="tj_139" class="t s0_139">peroxidation is the crucial step that promotes cell death called ferroptosis. Thus, the bacterial toxin BMAA </span>
<span id="tk_139" class="t s0_139">can alter microglial functions, and increase the rate of ferroptosis which are also one of the causes of sporadic </span>
<span id="tl_139" class="t s0_139">form of neurodegeneration. </span>
<span id="tm_139" class="t s2_139">Acknowledgments: </span><span id="tn_139" class="t s0_139">We are grateful to the DST-CSRI, India (DST/CSRI/2018/247). We also highly </span>
<span id="to_139" class="t s0_139">acknowledge the Shiv Nadar Foundation for supporting our research work. </span>
<span id="tp_139" class="t s3_139">P90: Development and validation of high throughput screening platform using genetic </span>
<span id="tq_139" class="t s3_139">cell line model for Parkinson’s disease and Gaucher Disease </span>
<span id="tr_139" class="t s2_139">Priya Gagansingh Thakur</span><span id="ts_139" class="t s0_139">, Sivaprakash Ramalingam </span>
<span id="tt_139" class="t s0_139">CSIR-IGIB, Mathura road, New Delhi, India; 2. ACSIR, Ghaziabad, India </span>
<span id="tu_139" class="t s2_139">Background: </span><span id="tv_139" class="t s0_139">The glucocerebrosidase 1 (GBA1) gene is the most common genetic risk factor for Parkinson's </span>
<span id="tw_139" class="t s0_139">disease (PD). The L444P mutation is the most frequent occurrence and is known to cause early onset and </span>
<span id="tx_139" class="t s0_139">severe forms of PD. The accumulation of misfolded mutant GCase leads to ER stress, which in turn causes </span>
<span id="ty_139" class="t s0_139">GCase to move to the cytoplasm and interact and stabilize soluble α-synuclein (αsyn) oligomers. This </span>
<span id="tz_139" class="t s0_139">accelerates the formation of pathological α-syn in PD pathology. </span>
<span id="t10_139" class="t s2_139">Approach: </span><span id="t11_139" class="t s0_139">HTS using patient-derived iPSCs can provide more accurate results, but it is a labor-intensive </span>
<span id="t12_139" class="t s0_139">and costly process to screen large libraries. To address these challenges, we have devised an economical </span>
<span id="t13_139" class="t s0_139">genetic model that employs low substrate concentration in SH-SY5Y cells carrying the L444P mutation. This </span>
<span id="t14_139" class="t s0_139">is supported by a platform that integrates fluorescence-based assay and flow cytometry to assess GCase </span>
<span id="t15_139" class="t s0_139">activity. </span>
<span id="t16_139" class="t s2_139">Results: </span><span id="t17_139" class="t s0_139">An initial screening of small molecule compounds (1st: approximately 1280 compounds, 2nd: </span>
<span id="t18_139" class="t s0_139">approximately 10,000 compounds) to boost GCase activity using the SH-SY5Y GBA1L444P/L444P and </span>
<span id="t19_139" class="t s0_139">GBA1L444P/+ cell lines. Additionally, our aim is to select the top 5 hit compounds through secondary </span>
<span id="t1a_139" class="t s0_139">screening of the top 10. </span>
<span id="t1b_139" class="t s2_139">Discussion: </span><span id="t1c_139" class="t s0_139">Assessment of the efficacy of these 5 compounds in alleviating the disease symptoms in human </span>
<span id="t1d_139" class="t s0_139">DA neurons differentiated from iPSCs of GBA1L444P/L444P-carrying. Evaluation of the potential of these </span>
<span id="t1e_139" class="t s0_139">compounds to mitigate the defects in dopaminergic differentiation of neuronal progenitor cells, improve </span>
<span id="t1f_139" class="t s0_139">mitochondria dysfunction, and prevent the accumulation of lipids, as well as to reduce susceptibility to α-syn </span>
<span id="t1g_139" class="t s0_139">PFF-induced PD. </span>
<span id="t1h_139" class="t s2_139">Acknowledgments: </span><span id="t1i_139" class="t s0_139">DBT, Government of India, CSIR, and DBT-JRF. </span>
<span id="t1j_139" class="t s3_139">P91: Graphene based nanomaterials to support neuronal growth and function post </span>
<span id="t1k_139" class="t s3_139">injury </span>
<span id="t1l_139" class="t s2_139">Priyadharishini Veeraraghavan </span>
<span id="t1m_139" class="t s0_139">Department of Biotechnology, PSG Institute of Advanced Studies, Coimbatore 641 004 </span>
<span id="t1n_139" class="t s0_139">Damage to neurons in the central nervous system (CNS) can have catastrophic consequences due to the loss </span>
<span id="t1o_139" class="t s0_139">of function and limited ability to recover. Injuries to the CNS occur in two stages: primary or acute injury, </span>
<span id="t1p_139" class="t s0_139">and secondary injury. The primary injury is the initial impact to the CNS, which leads to a prolonged </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
